<p>A. ChIP assay: LS174T cells were fixed with formalin, and then the chromatin was cleaved by sonication. The cleaved chromatin was then incubated with an anti-Sp1 antibody, a positive control RNA polII antibody, and a negative control IgG antibody. Finally, Sp1 binding at the <i>hTFF3</i> promoter was assessed by PCR amplification. B. HEK293 or LS174T cells were co-transfected with pGL3-300 and pRL-TK, and then treated with different concentrations of mithramycin A (a Sp1 inhibitor) for 24 h. Relative luciferase activity was measured and calculated. Data are presented as the mean ± SD (*P<0.05 <i>vs</i>. 0 µM mithramycin A).</p
<p>PC3 cells were treated with 100 nM of MTM-SDK, MTM-SK or vehicle (DMSO) for 24 h. A) Gene express...
<p>(A). The predicted STAT1 binding sites in the human GLS1 promoter, TSS is designated as +1. (B). ...
Deregulated activity of transcription factors (TFs) of the Sp/KLF family, like Sp1, Sp3 and Sp4, and...
<p><b>A.</b> DNA was isolated from HFL1 cells in each group and immunoprecipitated with antibodies a...
<p>Both pGL3-300 and a Sp1 over-expression plasmid were co-transfected into LS-174T cells and cultur...
<p>pGL3-300, pRL-TK, and Sp1 siRNA or non-targeted control siRNA were co-transfected into LS-174T ce...
<p>(A) Cells were treated with 1 µM Mithramycin A (MTM) for 18 or 36 hou...
<p>Purified Sp1 protein (panel A) or nuclear extract from DU145 cells (panels (B) to (D)) were incub...
<p>(A) and (B) Binding of Sp transcription factors to the core-promoter region of the <i>AFAP1L1</i>...
<p>(A) EMSA was performed to determine HIF-1α promoter binding complexes. 3T3-L1 cells were treated ...
<p>(A) The schematic representation of the mutation project. The constructs were then transiently tr...
<p><b>A</b>: EMSA showing the ability of Sp1 to bind to its two predicted sites <i>in vitro.</i> Sp1...
<p>(A) Schematic showing luciferase constructs with different lengths of the <i>CD3ζ</i> promoter. (...
<p><b>A</b>: Mithramycin A, an Sp1 inhibitor, reduces <i>TINF2</i> promoter-driven luciferase activi...
<p>(A) Schematic showing the <i>CD3ζ</i> promoter-luciferase pGL2-Zeta-3 construct. Arrows indicate ...
<p>PC3 cells were treated with 100 nM of MTM-SDK, MTM-SK or vehicle (DMSO) for 24 h. A) Gene express...
<p>(A). The predicted STAT1 binding sites in the human GLS1 promoter, TSS is designated as +1. (B). ...
Deregulated activity of transcription factors (TFs) of the Sp/KLF family, like Sp1, Sp3 and Sp4, and...
<p><b>A.</b> DNA was isolated from HFL1 cells in each group and immunoprecipitated with antibodies a...
<p>Both pGL3-300 and a Sp1 over-expression plasmid were co-transfected into LS-174T cells and cultur...
<p>pGL3-300, pRL-TK, and Sp1 siRNA or non-targeted control siRNA were co-transfected into LS-174T ce...
<p>(A) Cells were treated with 1 µM Mithramycin A (MTM) for 18 or 36 hou...
<p>Purified Sp1 protein (panel A) or nuclear extract from DU145 cells (panels (B) to (D)) were incub...
<p>(A) and (B) Binding of Sp transcription factors to the core-promoter region of the <i>AFAP1L1</i>...
<p>(A) EMSA was performed to determine HIF-1α promoter binding complexes. 3T3-L1 cells were treated ...
<p>(A) The schematic representation of the mutation project. The constructs were then transiently tr...
<p><b>A</b>: EMSA showing the ability of Sp1 to bind to its two predicted sites <i>in vitro.</i> Sp1...
<p>(A) Schematic showing luciferase constructs with different lengths of the <i>CD3ζ</i> promoter. (...
<p><b>A</b>: Mithramycin A, an Sp1 inhibitor, reduces <i>TINF2</i> promoter-driven luciferase activi...
<p>(A) Schematic showing the <i>CD3ζ</i> promoter-luciferase pGL2-Zeta-3 construct. Arrows indicate ...
<p>PC3 cells were treated with 100 nM of MTM-SDK, MTM-SK or vehicle (DMSO) for 24 h. A) Gene express...
<p>(A). The predicted STAT1 binding sites in the human GLS1 promoter, TSS is designated as +1. (B). ...
Deregulated activity of transcription factors (TFs) of the Sp/KLF family, like Sp1, Sp3 and Sp4, and...